Arkolith/Insider Trading/OPNT/Form 4

Ruth Matthew R.

Chief Commercial OfficerOPIANT PHARMACEUTICALS, INC. (OPNT) · full profile →Form 4 · filed Mar 3, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2023Disposed to issuer(D)19K$20.00$385K11K
Mar 2, 2023Disposed to issuer(D)11K$20.00$213K0
Mar 2, 2023Grant(A)2K—$02K
Mar 2, 2023Disposed to issuer(D)2K$20.00$40K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2023Disposed to issuer(D)50K—$00

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001385508-23-000073) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML